Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

REGOSARC – activity of regorafenib in advanced non-adipocytic STS

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 14.11.19
Views: 458
Rating:

Professor Jean-Yves Blay and Professor Florence Duffaud

Soft tissue sarcoma (STS) is a heterogenous group of cancers, consistive of over 80 histological entities and even more molecularly distinct subtypes. Although treatment of resectable is well-defined, guidance becomes limited in the metastatic setting. After doxorubicin-based treatment, there are a multitude of cytotoxic options; however, the activity of these agents varies depending on the specific subtype of STS.

The REGOSARC trial was a set of phase II trials that explored the activity of regorafenib in patients with different types of STS. A fifth cohort of this trial evaluated the effect of regorafenib after pazopanib in non-adipocytic STS.

Overall, the trial demonstrated positive (but different) effects across STS subtypes, indicating a potential future role in the management of sarcoma.

This independent educational activity is supported by an educational grant from Bayer Pharmaceuticals. The educational content has been developed by Liberum IME and validated by an independent steering committee; Bayer Pharmaceuticals have had no influence on the content of this education.

To earn CME credits and discover further publication to practice sessions, please visit Oncology knowledge into practice.

 

Related videos

follow us

SIOG metastatic renal cell carcinoma


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation